Central Retinal Artery Occlusion

Overview

Central retinal artery occlusion (CRAO) is a critical ophthalmic condition resulting from obstruction of the central retinal artery, leading to inner retinal infarction.¹ The infarcted retinal ganglion cells represent somata of optic nerve axons and are part of the central nervous system, making CRAO functionally equivalent to a small vessel stroke.² The condition requires urgent medical attention due to its devastating effect on visual function and association with systemic vascular disease.¹

CRAO consists of four distinct clinical entities: non-arteritic CRAO (NA-CRAO), transient NA-CRAO, NA-CRAO with cilioretinal artery sparing, and arteritic CRAO.³ Each subtype has different clinical characteristics, visual outcomes, and management considerations.³ Currently, there is no officially recommended or generally accepted evidence-based treatment for CRAO, in contrast to ischemic cerebral stroke.^1,2

Epidemiology & Risk Factors

Patients with CRAO face an increased risk of developing ischemic heart disease and cerebral stroke due to underlying atherosclerotic risk factors.¹ The condition shares risk factors with systemic vascular disease, reflecting its pathophysiologic similarity to other embolic and thrombotic events affecting the central nervous system.¹

The visual prognosis is poor, with a low chance of spontaneous visual recovery overall.¹ However, the incidence of spontaneous visual acuity improvement during the first 7 days differs significantly among the four CRAO subtypes. Among eyes with initial visual acuity of counting fingers or worse, visual acuity improved in 22% of NA-CRAO cases, 67% of NA-CRAO with cilioretinal artery sparing, and 82% of transient NA-CRAO cases during the first week.³ Arteritic CRAO shows no spontaneous improvement.³

Pathophysiology

CRAO results from obstruction of the central retinal artery, which supplies the inner retinal layers including the retinal ganglion cells.² The pathophysiology typically involves embolic or thrombotic occlusion in non-arteritic cases, while arteritic CRAO results from inflammatory arteritis affecting the ophthalmic circulation.³

The timing of irreversible retinal damage has important therapeutic implications. Traditional literature suggests that inner retinal infarction occurs after 90-240 minutes of complete CRAO, but this experimental evidence has been challenged.⁴ The retinal ganglion cells, being part of the central nervous system, may undergo infarction after only 12-15 minutes or less of non-perfusion, similar to other central nervous system tissue.⁴ This rapid timeline helps explain why therapeutic interventions are often ineffective when initiated after symptom onset.⁴ However, many CRAOs are incomplete occlusions and may potentially benefit from therapy after longer intervals.⁴

Clinical Presentation

Patients with CRAO present with acute, sudden loss of vision that is typically painless.¹ The visual impairment is usually severe, often reducing visual acuity to counting fingers or worse.⁵ The onset is sudden and dramatic, reflecting the acute ischemic event affecting the inner retina.

Contrary to prevalent belief, spontaneous improvement in both visual acuity and visual fields can occur, mainly during the first 7 days after onset.³ The pattern and likelihood of improvement vary significantly depending on the CRAO subtype. In NA-CRAO with initial vision of counting fingers or worse, visual acuity remained stable in 66% of cases during the first week, while 22% improved and 12% deteriorated.³ Transient NA-CRAO shows the highest rate of improvement at 82%, while arteritic CRAO shows no spontaneous improvement.³

Exam Findings

Characteristic examination findings in CRAO include:

• Cherry-red spot appearance at the macula, representing the contrast between the infarcted pale retina and the preserved choroidal circulation visible through the thin fovea⁴
• Retinal whitening or opacification reflecting inner retinal edema from ischemia
• Visible embolic material or plaques in the retinal arterial circulation in some cases
• Attenuated retinal arterioles
• Relative afferent pupillary defect in unilateral cases
• Distinct findings depending on CRAO subtype, with cilioretinal artery sparing showing preserved perfusion in the distribution of this vessel when present³

Various ophthalmic examination modalities have provided useful assessments for characterizing CRAO and its pathophysiologic features.⁵

Classification

CRAO is classified into four distinct clinical entities, each with different clinical characteristics, visual outcomes, and management approaches:³

• Non-arteritic CRAO (NA-CRAO): The most common form, typically caused by embolic or thrombotic occlusion without underlying arteritis. Visual outcome is generally poor, with 22% showing improvement during the first 7 days among those with initial counting fingers vision or worse.³

• Transient NA-CRAO: A transient ischemic event affecting the retinal circulation with spontaneous resolution. This subtype has the best prognosis, with 82% showing visual improvement during the first week.³

• NA-CRAO with cilioretinal artery sparing: Preserved perfusion through a cilioretinal artery when present provides continued blood supply to a portion of the macula, resulting in better visual outcomes. Among patients with initial severe vision loss, 67% improved during the first week.³

• Arteritic CRAO: Results from inflammatory arteritis, typically giant cell arteritis, affecting the ophthalmic circulation. This subtype shows no spontaneous improvement and requires urgent systemic treatment to prevent involvement of the fellow eye and other vascular territories.³

Differential Diagnosis

• Ophthalmic artery occlusion (more severe ischemia affecting both inner and outer retina)
• Branch retinal artery occlusion (sectoral rather than global inner retinal involvement)
• Transient monocular vision loss/amaurosis fugax (transient with complete resolution)
• Posterior ischemic optic neuropathy (optic nerve dysfunction without typical retinal findings)
• Acute optic neuritis (usually younger patients, pain with eye movement, different examination findings)
• Severe hypertensive retinopathy (bilateral findings, systemic hypertension)
• Retinal vein occlusion (hemorrhagic rather than pale retina)
• Vitreous hemorrhage (obscured retinal view rather than visible retinal pathology)
• Retinal detachment (different examination findings, different temporal profile)

Management

There is currently no officially recommended or generally accepted evidence-based treatment for non-arteritic CRAO, in contrast to the well-established treatment protocols for ischemic cerebral stroke.^1,2 The widely divergent and controversial therapeutic options reflect the desperation of treating physicians and conflicting study results.²

Recent studies have shown that administration of local intra-arterial thrombolytic agents not only has no beneficial effect but can be harmful.³ Conservative therapies have demonstrated limited benefits compared with the natural course of disease.⁵

Surgical interventions have evolved with assistance from surgical instruments and surgical robots, though these options are not widely recognized by ophthalmologists.⁵ Pars plana vitrectomy plus endovascular surgery has received considerable interest because of its potential efficacy, though further validation is needed.⁵

Critical management priorities include:

• Urgent evaluation to rule out arteritic CRAO, which requires immediate systemic corticosteroid treatment to prevent fellow eye involvement
• Investigation to identify the underlying cause of occlusion³
• Assessment and management of cardiovascular and cerebrovascular risk factors to prevent future vascular events³
• Recognition that the therapeutic window may be very narrow given the potential for retinal infarction within 12-15 minutes of complete occlusion⁴
• Understanding that many occlusions are incomplete and the natural history varies by CRAO subtype, which should inform treatment decisions^4,5

Complications

The primary complication of CRAO is severe, permanent visual loss, with many patients left with counting fingers vision or worse.⁵ The visual prognosis is poor overall, with low rates of spontaneous visual recovery.¹

Systemic complications and associated conditions include:

• Increased risk of ischemic heart disease due to shared atherosclerotic risk factors¹
• Increased risk of cerebral stroke, as CRAO often reflects systemic vascular disease¹
• In arteritic CRAO, risk of fellow eye involvement and other vascular territory complications if arteritis is not promptly treated³
• Potential harm from some therapeutic interventions, particularly intra-arterial thrombolytic agents³

The condition has medical-legal implications, particularly when CRAO complicates therapeutic interventions or results from inadvertent ocular compression during procedures such as prone anesthesia.⁴

Clinical Pearls

• CRAO is best conceptualized as a 'stroke of the eye,' representing small vessel stroke affecting the central nervous system tissue of the retinal ganglion cells^1,2
• Spontaneous visual improvement does occur and is most likely during the first 7 days after onset, with rates varying significantly by CRAO subtype³
• The four distinct CRAO subtypes have markedly different prognoses: transient NA-CRAO has the best outcome (82% improvement), followed by NA-CRAO with cilioretinal sparing (67%), then NA-CRAO (22%), while arteritic CRAO shows no improvement³
• Retinal infarction may occur after only 12-15 minutes of complete occlusion, not the 90-240 minutes traditionally cited, though many occlusions are incomplete⁴
• The short therapeutic window and uncertainty about completeness of occlusion present significant challenges for intervention⁴
• Intra-arterial thrombolytic therapy has been shown to be potentially harmful and should be avoided³
• It is essential to distinguish between treatment effects and the natural course of disease when evaluating therapeutic interventions, as outcomes vary substantially by CRAO subtype⁵
• Urgent evaluation for arteritic causes is critical, as arteritic CRAO requires immediate systemic treatment³

Common Pitfalls

• Assuming all CRAOs have identical prognoses without recognizing the four distinct subtypes with different natural histories³
• Attributing visual improvement to therapeutic interventions without accounting for the significant rate of spontaneous improvement during the first week³
• Relying on the traditional 90-240 minute window for retinal survival, when infarction may occur much more rapidly with complete occlusion⁴
• Using intra-arterial thrombolytic agents, which have been shown to be ineffective and potentially harmful³
• Failing to urgently evaluate for arteritic CRAO, which requires immediate treatment to prevent devastating bilateral vision loss³
• Generalizing treatment efficacy across all CRAO types without recognizing that incomplete occlusions may respond differently than complete occlusions⁴
• Not investigating and addressing underlying systemic vascular risk factors that increase the patient's risk of cardiac and cerebrovascular events^3,1
• Misinterpreting the natural course of disease as treatment effect when evaluating therapy outcomes⁵